Evidence map›Paper›PMID 33425894›Full record

ArticleFrontiers in cell and developmental biology2020

Alkaline Phosphatases Account for Low Plasma Levels of Inorganic Pyrophosphate in Chronic Kidney Disease.

Audrey Laurain, Isabelle Rubera, Christophe Duranton, Frank Rutsch, Yvonne Nitschke, Elodie Ray, Sandor Vido, Antoine Sicard, Georges Lefthériotis, Guillaume Favre

Open access · goldAbstract read
In one paragraph

Article in Frontiers in cell and developmental biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Vitamin B6 challenge as a tool for detecting ALPL mutations and diagnosing hypophosphatasia.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2025
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Oral pyrophosphate protects Abcc6Journal of molecular medicine (Berlin, Germany) · 2024
    Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Audrey LaurainFaculty of Medicine, Côte d'Azur University, Nice, France.
Isabelle RuberaUMR 7073, Laboratory of Physiology and Molecular Medicine (LP2M), Centre National de la Recherche Scientifique, Nice, France.
Christophe DurantonUMR 7073, Laboratory of Physiology and Molecular Medicine (LP2M), Centre National de la Recherche Scientifique, Nice, France.
Frank RutschDepartment of General Pediatrics, Muenster University Children's Hospital, Muenster, Germany.
Yvonne NitschkeDepartment of General Pediatrics, Muenster University Children's Hospital, Muenster, Germany.
Elodie RayDepartment of Vascular Medicine and Surgery, University Hospital, Nice, France.
Sandor VidoNephrology Department, University Hospital, Nice, France.
Antoine SicardFaculty of Medicine, Côte d'Azur University, Nice, France.
Georges LefthériotisFaculty of Medicine, Côte d'Azur University, Nice, France.
Guillaume FavreFaculty of Medicine, Côte d'Azur University, Nice, France.
Laboratoire de PhysioMédecine Moléculaire · FRCentre National de la Recherche Scientifique · FRUniversity Hospital Münster · DEObservatoire de la Côte d’Azur · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionPatients on dialysis and kidney transplant recipients (KTR) present the syndrome of mineral and bone disorders (MBD), which share common traits with monogenic calcifying diseases related to disturbances of the purinergic system. Low plasma levels of inorganic pyrophosphate (PP PATIENTS AND

methodsWe included 10 controls, 10 patients on maintenance dialysis, 10 early KTR 3 ± 1 months after transplantation and nine late KTR 24 ± 3 months after transplantation. We measured aortic calcifications, plasma and urine levels of PP

resultsLow PP DISCUSSION: Patients on dialysis and KTR have low plasma levels of PP

Indexed as

alkaline phosphatase activityhemodialysiskidney transplantmineral and bone disorder (CKD-MBD)purinergic mechanismspyrophosphate

Identifiers

PMID33425894
PMCPMC7793922
OpenAlexW3109547997

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.